The Sugar Beat

Will Wegovy Be of Little Use for Weight Loss? The weight loss drug heralded as a 'game changer' may be of little use unless we take care of a few hurdles first, says Dr Akshay Jain.
Experts And Viewpoints, August 12, 2021
Top Studies, Highlights From ADA 2021 Drs Akshay Jain and Harpreet Bajaj give us their takes on the clinically relevant highlights from ADA 2021.
Experts And Viewpoints, July 09, 2021
Disparities in SGLT2i Use: Patient Barriers or Physician Bias? A recent study suggests that although the use of SGLT2 inhibitors has increased overall, certain groups are not being prescribed these medications. Dr Akshay Jain looks into possible reasons why.
Experts And Viewpoints, May 12, 2021
EASD 2020 GLP-1 Receptor Agonists at EASD 2020: Poster Pearls Dr Akshay Jain shares his top poster picks on GLP-1 receptor agonists from this year's EASD virtual meeting.
Experts And Viewpoints, December 11, 2020
EASD 2020 New Diabetes Guidelines: 'Treat to Mitigate' Dr Akshay Jain reviews the new position statement from Primary Care Diabetes Europe on the management of type 2 diabetes.
Experts And Viewpoints, October 29, 2020
EASD 2020 Once-Weekly 'Centennial Insulin': Will It Live Up to the Promise? One hundred years after the discovery of insulin, we are approaching a new frontier in diabetes management, says Dr Harpreet Bajaj.
Experts And Viewpoints, September 24, 2020
Obesity and the Bitter Pill of Truth Obesity is encountered ubiquitously in clinical practice, with rates continuing to rise -- but why? Perhaps it's time we face the truth, says Dr Akshay Jain.
Experts And Viewpoints, September 23, 2020
CGM in Type 2 Diabetes: Invaluable or Too Expensive? Is the value of using CGM in people with type 2 diabetes worth the cost? Dr Akshay Jain comments on a debate from ADA 2020.
Experts And Viewpoints, July 21, 2020
VERTIS-CV Results 'Disappoint,' Raise More Questions The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.
Experts And Viewpoints, July 02, 2020
Is COVID-19 Fueling the Fire of Opinion-Based Medicine? This pandemic is causing people to turn to the 'pseudosciences' in their desperation to quickly save the world, writes Harpreet Bajaj.
Experts And Viewpoints, June 04, 2020
The Links Between COVID-19 and Diabetes, Known and Unknown Dr Harpreet Bajaj summarizes the known and unknown links between diabetes and COVID-19, focusing on three clinical questions.
Experts And Viewpoints, May 07, 2020
Cardios, Nephros, PCPs -- We're All Diabetologists Now Newer diabetes medications are proving effective in reducing CV events, hospitalizations for heart failure, and progression to dialysis. So where do these drugs belong?
Experts And Viewpoints, March 05, 2020
Top 5 Diabetes Highlights From 2019 For the first time in several years, a cardiovascular outcomes trial may not be the most exciting diabetes news of the year. Here are 2019's highlights from Dr Harpreet Bajaj.
Experts And Viewpoints, January 17, 2020
Recreational Marijuana in Diabetes: Not All Fun and Games Dr Harpreet Bajaj discusses the potential harms of recreational cannabis use in people with type 1 and type 2 diabetes.
Experts And Viewpoints, October 02, 2019
'Poised on a Paradigm Shift': The REWIND and DECLARE Trials Drs Harpreet Bajaj and Akshay Jain, coauthors of the Sugar Beat column, come together to discuss the results and clinical implications of the REWIND and DECLARE trials.
Experts And Viewpoints, June 14, 2019
CREDENCE Takes SGLT2 Inhibitors 'to the Next Level' What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.
Experts And Viewpoints, April 25, 2019
Fielding the Dangers of Fasting and Feasting With Diabetes Are you prepared to safely guide your Muslim patients with diabetes through Ramadan, their holy month of fasting? Here's what you need to know.
Experts And Viewpoints, April 18, 2019
Diabetes 360: A Plan to Quell the 'Tsunami' of Diabetes Diabetes Canada's 360? framework can revolutionize diabetes prevention policies across the globe, says Harpreet Bajaj.
Experts And Viewpoints, March 25, 2019
Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' Dr Akshay Jain discusses the potential implications of a generic DPP-4 inhibitor for the management of type 2 diabetes that may soon enter the US market.
February 08, 2019
The Artificial Pancreas Has Arrived in Canada: What to Expect Dr Harpreet Bajaj discusses the first artificial pancreas that has been approved for use in Canada--what to expect, anticipated challenges, and learnings from experiences in the United States.
Experts And Viewpoints, January 02, 2019

No Results